ArticleJournal for immunotherapy of cancer2021
CD8
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study.Journal for immunotherapy of cancer · 2026Trial
- Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors.Cell reports. Medicine · 2026Article
- Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.Journal for immunotherapy of cancer · 2026Article
- Human GPR174 deficiency drives polyclonal lymphoproliferative disease via defects in T cell function.medRxiv : the preprint server for health sciences · 2026Article
- Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine: Immune Correlates in Long-Term Survivors.Biomedicines · 2025Article
- Progressive accumulation of circulating CD27Experimental & molecular medicine · 2025Article
- Deciphering immune predictors of immunotherapy response: A multiomics approach at the pan-cancer level.Cell reports. Medicine · 2025Article
- Increased long-term central memory T cells in patients with retreatment pulmonary tuberculosis.Frontiers in immunology · 2025Article
- Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer.Biomarker research · 2024Article
- Memory inflation: Beyond the acute phase of viral infection.Cell proliferation · 2024Review
- Flow Cytometry Analyses of Meningioma Immune Cell Composition Using a Short, Optimized Digestion Protocol.Cancers · 2024Article
- Single Cell Atlas: a single-cell multi-omics human cell encyclopedia.Genome biology · 2024Article
- New T-lymphocyte subpopulations and their characteristics: Challenges to the classical division of lymphocyte function.Central-European journal of immunology · 2024Review
- Characterizing CD8+ TEMRA Cells in CP/CPPS Patients: Insights from Targeted Single-Cell Transcriptomic and Functional Investigations.ImmunoTargets and therapy · 2024Article
- Review
- CD5 Expression Dynamically Changes During the Differentiation of Human CD8Immune network · 2023Article
- An immunosuppressed microenvironment distinguishes lateral ventricle-contacting glioblastomas.JCI insight · 2023Article
- The role of the CD8+ T cell compartment in ageing and neurodegenerative disorders.Frontiers in immunology · 2023Review
- Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.Cancer immunology research · 2022Article
- Novel Biomarkers in Lung Cancer and Chronic Lung Diseases: From the Systematic Perspective ofJournal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD8
methodsWe analyzed primary tumors and peripheral blood samples from 26 patients with non-small cell lung cancer and analyzed their phenotypes and functional characteristics using flow cytometry, RNA-sequencing, and bioinformatics.
resultsWe found that tumor-infiltrating Temra (tilTemra) cells largely differ from peripheral blood Temra (pTemra), with distinct transcriptomes and functional properties. Notably, although majority of the pTemra was CD27
conclusionsThese data suggest a complex interplay between CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.